Clinical trial NCT00446134 - References

Chronic Hepatitis C — Taribavirin Phase 2 Dose Finding Study for the Treatment of Hepatitis C Virus (HCV)

Citation(s)

•   Lawitz E, Muir A, Poordad F, et al
  Treatment week 24 results of weight-based taribavirin versus weight-based ribavirin, both with peginterfon alfa-2b, in naive chronic hepatitis C, genotype 1 patients. Hepatology. 2008;48 Suppl 1:433A
•   Poordad F, Lawitz E, Chun E, Hammond J
  Treatment week 12 results of weight-based taribavirin versus weight-based ribavirin, both with peginterferon alfa-2b, in naive chronic hepatitis C, genotype 1 patients. J Hepatol. 2008;48 Suppl 2:S373
•   Poordad F, Lawitz E, Hassanein T, et al
  Sustained virologic response results for weight-based taribavirin versus weight-based ribavirin, in naive chronic hepatitis C, genotype 1 patients. Hepatology. 2009;50 Suppl 1:334A
•   Poordad F, Lawitz E, Pozza R, et al
  Efficacy and safety of weight-based regimens of taribavirin or ribavirin, given with peginterferon alfa-2b, 12 weeks after treatment (SVR12) in naive patients with genotype 1 hepatitis C. J Hepatol. 2009;50 Suppl 1:S8

Phase 2 Comparison of Weight-based Doses of Taribavirin Combined With Peginterferon Alfa-2b Versus Ribavirin Combined With Peginterferon Alfa-2b in Therapy-naïve Patients With Chronic Hepatitis C Virus Genotype 1 Infection

Details for clinical trial NCT00446134